News Releases
AGN NeuroScience and AGN Pharmaceuticals News
Listing of News Releases
- Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
- Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
- Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
- Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
- Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
- Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
- Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
- Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
- Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
- Algernon Pharmaceuticals Announces Closing of Rights Offering
- Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
- Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application
- Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
- Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M
- Algernon Pharmaceuticals Announces Launch of Rights Offering